Details

Semaglutide is a new weekly glucagon-like peptide-1 (GLP-1) receptor agonist, which has a significant effect on blood sugar control and weight loss in type 2 diabetes (T2DM). Semaglutide has been shown to be possible to improve type 2 diabetes. The positive recommendations of the advisory committee mark an important step in providing semaglutide to patients with type 2 diabetes in the United States.

In humans, semaglutide is chemically similar to glucagon-like peptide-1 (GLP-1). Semaglutide is an analog of glucagon-like peptide-1 (GLP-1) and functions as a GLP-1 agonist. Cerebrovascular glucose can also improve cardiovascular function, reduce the risk of stroke by 39%, and reduce the risk of myocardial infarction. In addition, Semaglutide has shown significant beneficial effects on cardiovascular outcomes and safety similar to other GLP-1 receptor agonists.


Limitations of Use

• Semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
• Semaglutide has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
• Semaglutide is not a substitute for insulin. Semaglutide is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.